Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe
- EMEA Innovative Medicine
- Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe
Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe
- X (Twitter)
Copy link